Fragility hip fractures and their associated morbidity and mortality pose a global healthcare problem. Several pharmaceutical products have been postulated to alter bone architecture and contribute to fragility hip fractures. We searched four electronic databases from inception to September 2017. Inclusion criteria were the following: (1) adult patients with fragility hip fractures, (2) full text in English, (3) minimum one-year follow-up, and (4) reporting of at least one risk factor. To minimize heterogeneity among the studies, we performed subgroup analyses. Whenever heterogeneity remained significant, we employed random effect meta-analysis for data pooling. Thirty-eight studies were included, containing 1,244,155 subjects and 188,966 cases of fragility hip fractures. Following medications were significantly associated with fragility hip fractures: Antidepressants (OR 2.07, 95% CI 1.98–2.17), antiparkinsonian drugs (OR 2.21, 95% CI 1.15–4.24), antipsychotic drugs (OR 2.0, 95% CI 1.50–2.66), anxiolytic drugs (OR 1.44, 95% CI 1.19–1.75), benzodiazepines (OR 1.84, 95% CI 1.26–2.69), sedatives (OR 1.33, 95% CI 1.14–1.54), systemic corticosteroids (OR 1.65, 95% CI 1.37–1.99), H₂ antagonists (OR 1.21, 95% CI 1.18–1.24), proton pump inhibitors (OR 1.41, 95% CI 1.16–1.71), and thyroid hormone (OR 1.29, 95% CI 1.13–1.47). Hormone replacement therapy with estrogen (HRT) was associated with decreased risk of hip fracture (OR 0.80, 95% CI 0.65–0.98). There are several medications associated with sustaining a fragility hip fracture. Medical interventions should be considered for patients on these medications, including information about osteoporosis and fracture prevention.

脆弱的髋部骨折及其相关的发病率和死亡率构成了全球性的医疗保健问题。已经提出了几种药品来改变骨骼结构并导致髋部脆性骨折。从开始到2017年9月，我们搜索了四个电子数据库。纳入标准如下：（1）成年脆性髋部骨折患者；（2）英文全文；（3）至少一年的随访；（4）报告至少一种危险因素。为了使研究之间的异质性最小化，我们进行了亚组分析。只要异质性仍然很显着，我们就采用随机效应荟萃分析进行数据汇总。包括38个研究，包括1,244,155名受试者和188,966例脆性髋部骨折病例。_2种拮抗剂（OR 1.21，95％CI 1.18-1.24），质子泵抑制剂（OR 1.41，95％CI 1.16-1.71）和甲状腺激素（OR 1.29，95％CI 1.13-1.47）。激素替代激素治疗可降低髋部骨折风险（OR 0.80，95％CI 0.65-0.98）。有几种与维持脆性髋部骨折有关的药物。应考虑对使用这些药物的患者进行医疗干预，包括有关骨质疏松症和骨折预防的信息。